Literature DB >> 11958275

Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy.

A López-Candales1.   

Abstract

Diabetes mellitus is associated with a markedly increase prevalence of coronary artery disease, found to be as high as 55% (Lyons, 1993). The metabolic syndrome X, a multifaceted clinical entity produced by genetic, hormonal and lifestyle factors which occurs frequently in the general population, has been associated as an end point in patients with diabetes (Timar, Sestier et al., 2000). New data suggests that a clustering of truncal obesity, glucose intolerance or non-insulin dependent diabetes mellitus, dyslipidemia and essential hypertension are key components of this metabolic syndrome X (Timar, Sestier et al., 2000). In fact, the metabolic syndrome X has been shown to precede frank diabetes in a substantial number of patients; hence similar multiple cardiac risk factors will be found in this population. Thus, primary care providers should identify patients at an early stage so that appropriate treatment can be readily instituted. The goal of this review is to summarize criteria for diagnosis of patients with the metabolic syndrome X and therapeutic targets of each individual component is analyzed in a attempt to reduce cardiovascular events and improve clinical outcome based on the available clinical data.

Entities:  

Mesh:

Year:  2001        PMID: 11958275

Source DB:  PubMed          Journal:  J Med        ISSN: 0025-7850


  12 in total

Review 1.  Fibrates for treatment of the metabolic syndrome.

Authors:  Kevin C Maki
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

2.  Report of practicability of a 6-month home-based functional electrical stimulation cycling program in an individual with tetraplegia.

Authors:  David R Dolbow; Ashraf S Gorgey; Jewel R Moore; David R Gater
Journal:  J Spinal Cord Med       Date:  2012-05       Impact factor: 1.985

Review 3.  Rational approaches, design strategies, structure activity relationship and mechanistic insights for therapeutic coumarin hybrids.

Authors:  Harbinder Singh; Jatinder Vir Singh; Kavita Bhagat; Harmandeep Kaur Gulati; Mohit Sanduja; Nitish Kumar; Nihar Kinarivala; Sahil Sharma
Journal:  Bioorg Med Chem       Date:  2019-06-22       Impact factor: 3.641

Review 4.  Phytotherapy in diabetes: Review on potential mechanistic perspectives.

Authors:  Hanan S El-Abhar; Mona F Schaalan
Journal:  World J Diabetes       Date:  2014-04-15

Review 5.  Growth, body composition and hormonal axes in children and adolescents.

Authors:  A D Rogol
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

6.  Synthesis, α-glucosidase inhibition and molecular docking studies of novel thiazolidine-2,4-dione or rhodanine derivatives.

Authors:  Guang-Cheng Wang; Ya-Ping Peng; Zhen-Zhen Xie; Jing Wang; Ming Chen
Journal:  Medchemcomm       Date:  2017-05-31       Impact factor: 3.597

7.  Improvements of insulin resistance in ovariectomized rats by a novel phytoestrogen from Curcuma comosa Roxb.

Authors:  Mujalin Prasannarong; Vitoon Saengsirisuwan; Pawinee Piyachaturawat; Apichart Suksamrarn
Journal:  BMC Complement Altern Med       Date:  2012-03-30       Impact factor: 3.659

8.  Association of Insulin Resistance with Glucose and Lipid Metabolism: Ethnic Heterogeneity in Far Western China.

Authors:  Yi-Zhong Yan; Ru-Lin Ma; Jing-Yu Zhang; Jia He; Jiao-Long Ma; Hong-Rui Pang; La-Ti Mu; Yu-Song Ding; Heng Guo; Mei Zhang; Jia-Ming Liu; Dong-Sheng Rui; Kui Wang; Shu-Xia Guo
Journal:  Mediators Inflamm       Date:  2016-12-22       Impact factor: 4.711

9.  Mediation of Endogenous beta-endorphin by Tetrandrine to Lower Plasma Glucose in Streptozotocin-induced Diabetic Rats.

Authors:  Jen-Hao Hsu; Yang-Chang Wu; Shorong-Shii Liou; I -Min Liu; Lee-Wen Huang; Juei-Tang Cheng
Journal:  Evid Based Complement Alternat Med       Date:  2004-09-01       Impact factor: 2.629

10.  Herbal medicine as an alternative medicine for treating diabetes: the global burden.

Authors:  Geeta Watal; Preeti Dhar; Sharad Kr Srivastava; Bechan Sharma
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.